Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 8 November 2017

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018

Infant Bacterial Therapeutics AB    

Published: 21:00 CET 08-11-2017 /GlobeNewswire /Source: Infant Bacterial Therapeutics AB / : IBT B /ISIN: SE0008015259

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018

The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect representative to be a member of the Nomination Committee together with the Chairman of the Board. In the establishment of the Nomination Committee, the ownership ratios as of June 30, 2017 shall determine the largest shareholders in terms of voting rights. The representative of the largest shareholder in the Nomination Committee at that time shall be the chairman of the election committee. If any of the three largest shareholders waives their right to appoint a member of the Nomination Committee, the next largest shareholder shall be allowed to appoint a member of the Nomination Committee.

 

In accordance with the AGM's decision, the Nomination Committee was formed and consists of, apart from the chairman of Infant Bacterial Therapeutics AB's Board of Directors, Peter Rothschild, by Per-Erik Andersson, representative of the company's largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, representative of the company's second largest shareholder Banque Öhman SA as well as Jannis Kitsakis, representative of the company's third largest shareholder, the Fourth Swedish National Pension Fund. All members of the Nomination Committee, apart from Peter Rothschild, are independent in relation to the company and company management.

 

The nomination committee is reached via the election committee chairman, Per-Erik Andersson, at pea@pealaw.se, or by telephone: +46 70-537 98 92.

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 



PR 20171108 NomComm ENG



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Infant Bacterial Therapeutics AB, Bryggargatan 10, Stockholm 111 21, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.